OTC Probiotics Face Challenging Regulatory Framework
This article was originally published in The Tan Sheet
Executive Summary
The development of OTC drugs based on probiotics requires a regulatory system more receptive to research on the microorganisms' use as therapeutic ingredients, according to microbiologist Gary Huffnagle.
You may also be interested in...
Health Canada Responds To Probiotics Proliferation With Revised Regulation
Canada’s evolving regulatory framework for probiotics may offer lessons for the U.S., though statutes constrain how much FDA can change.
NuMe Among Firms With Gut Feeling About Burgeoning Prebiotics Space
Prebiotics could grow from a currently “nonexistent” market to surpass the flourishing probiotics category in both revenues and supporting science, the chief executive of a prebiotics developer says.
Schiff Nutrition Gains Probiotics Ingredient, Brands From Ganeden
Schiff Nutrition International makes a $40 million investment in probiotic supplements by acquiring worldwide exclusive rights to the GanedenBC30 strain and a pair of consumer probiotics brands.